Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
OBiO Technology
Shanghai, Chinaobio-tech.com ↗
- Ownership
- Private
- Employees
- ~731
- Development stage
- Other
01
Overview
OBiO Technology provides end-to-end CRO/CDMO services for gene and cell therapies. It has supported over 25 IND approvals for clients globally (including eight FDA INDs), operates multiple GMP facilities in Shanghai, and offers proprietary vector development platforms. The company enables process development, analytical method development, clinical/commercial manufacturing of viral vectors/oncolytic viruses/cell therapies, plasmid construction, viral packaging services, recombinant protein/exosome production, and cell storage solutions. It is recognized for its cGMP-compliant operations and international reach with branches outside China.
- Modalities
- Gene therapyCell therapyRecombinant proteinExosome-based therapy
- Industry
- Contract Research Organization
02
Partnerships
CHINAGENEGE Medical
Beyond the preview
Go deeper on OBiO Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBiO Technology.